{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:16:15Z","timestamp":1786972575519,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,12,4]],"date-time":"2010-12-04T00:00:00Z","timestamp":1291420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effectiveness and safety of the administration of misoprostol, an orally active prostaglandin, in addition to routine uterotonic therapy as part of the active management of the third stage of labor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The present study was a hospital\u2010based, decentralized, multi\u2010center, randomized, placebo\u2010controlled, double\u2010blind trial. We enrolled 1103 women (out of a target sample size of 1180) at 4 hospitals in South Africa, Uganda, and Nigeria. Participants received a sublingual dose of 400 \u03bcg of misoprostol or a placebo, in addition to standard active management of the third stage of labor, after vaginal birth.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The baseline characteristics of the participants were comparable. The difference in the primary outcome of blood loss of 500 mL or more within 1 hour of randomization was not significant between the 2 groups (misoprostol 22\/546 [4.0%] versus placebo 35\/553 [6.3%]; relative risk, 0.64; 95% confidence interval, 0.38\u20131.07). Shivering and pyrexia occurred more frequently in the misoprostol group. No maternal deaths occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study did not confirm a beneficial effect of administering 400 \u03bcg of misoprostol, in addition to routine uterotonic therapy, during the third stage of labor, but was consistent with other trials showing a cumulative modest benefit. Where routine uterotonics are available for prophylactic use, any potential benefit of misoprostol might not outweigh the likelihood of adverse effects. Trial registered on clinical <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/trials.gov\">trials.gov<\/jats:ext-link>: NCT 00124540.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.ijgo.2010.08.019","type":"journal-article","created":{"date-parts":[[2010,12,5]],"date-time":"2010-12-05T09:14:39Z","timestamp":1291540479000},"page":"98-102","source":"Crossref","is-referenced-by-count":23,"title":["Administration of 400 \u03bcg of misoprostol to augment routine active management of the third stage of labor"],"prefix":"10.1002","volume":"112","author":[{"given":"G. Justus","family":"Hofmeyr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bukola","family":"Fawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kidza","family":"Mugerwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Patrick","family":"Godi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Blignaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindeka","family":"Mangesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandisa","family":"Singata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/0144361021000003555"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2002.00892.x"},{"key":"e_1_2_6_4_2","volume-title":"Report of confidential enquiries into maternal deaths in the United Kingdom 1991\u20131993","author":"Department of Health","year":"1996"},{"issue":"7","key":"e_1_2_6_5_2","first-page":"CD007412","article-title":"Active versus expectant management for women in the third stage of labour","author":"Begley C.M.","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"e_1_2_6_6_2","first-page":"CD001808","article-title":"Prophylactic oxytocin for the third stage of labour","author":"Cotter A.M.","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"e_1_2_6_7_2","first-page":"CD005456","article-title":"Prophylactic use of ergot alkaloids in the third stage of labour","author":"Liabsuetrakul T.","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"e_1_2_6_8_2","first-page":"CD000201","article-title":"Prophylactic ergometrine\u2013oxytocin versus oxytocin for the third stage of labour","author":"McDonald S.J.","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1999.tb08266.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05835-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(02)00355-X"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2001.00014.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00512.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.08.055715"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(02)00020-6"},{"key":"e_1_2_6_16_2","unstructured":"World Health Organisation.WHO recommendations for the prevention of postpartum haemorrhage.http:\/\/www.who.int\/making_pregnancy_safer\/publications\/WHORecommendationsforPPHaemorrhage.pdf Published 2007. Accessed 2010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540080059030"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2002.126293"},{"issue":"5","key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00006250-200305000-00017","article-title":"Oral misoprostol for the third stage of labor: a randomized controlled trial","volume":"101","author":"Cali\u015fkan E.","year":"2003","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_20_2","unstructured":"Fawole AO Sotiloye OS Hunyinbo KI Umezulike AC Okunlola MA Adekanle DA et al. Misoprostol and routine uterotonics for prevention of postpartum hemorrhage: A double\u2010blind randomized placebo controlled trial. Int J Gynecol Obstet (in press)."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61924-3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2010.02564.x"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0020729210005011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0020729210005011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2010.08.019","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2010.08.019","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.ijgo.2010.08.019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T09:42:28Z","timestamp":1711446148000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1016\/j.ijgo.2010.08.019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1016\/j.ijgo.2010.08.019"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgo.2010.08.019","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}